Miranda Vivian C, Souza Ramon O, Gallotti Bruno, de Oliveira Marcos F A, Faria Ana Maria C, Nicoli Jacques R, Ferreira Enio, Machado Denise C C, Martins Flaviano S
Department of Microbiology, Institute of Biological Sciences, Federal University of Minas Gerais, Av. Antônio Carlos, Belo Horizonte, MG, 6627, 30270-901, Brazil.
Research and Development Department, Ezequiel Dias Foundation, FUNED, Belo Horizonte, MG, Brazil.
Probiotics Antimicrob Proteins. 2024 Oct 15. doi: 10.1007/s12602-024-10386-1.
Food allergy is a pathological condition caused by a disruption of oral tolerance. This condition leads to a pro-inflammatory environment that culminates in symptoms that varies from abdominal pain to anaphylaxis and death. The gold standard treatment consists of removing the food that triggers the allergy from diet. However, this conduct can cause nutritional impairment and social restrictions. Therefore, the need for new treatment strategies is notorious. In this context, probiotics are investigated due to their immunomodulatory mechanisms. Therefore, the objective of the present work is to investigate the probiotic potential of a mixture of four probiotic strains (Probiatop®) in an in vivo model of food allergy to ovalbumin (OVA). Our results demonstrated that oral administration of Probiatop® attenuated weight loss and diminished significantly anti-OVA IgE and IgG1 levels. Furthermore, it mitigated proximal jejunum injury, neutrophil recruitment and local IL17 levels. In addition, the probiotic mixture modulated positively the gut microbiota composition by decreasing the levels and frequency of Staphylococcus and yeast. In summary, our data suggest that Probiatop® has the potential to alleviate important symptoms of IgE-mediated food allergy, suggesting its probiotic potential as an adjuvant in the treatment of ovalbumin food allergy.
食物过敏是一种由口服耐受破坏引起的病理状态。这种状态会导致促炎环境，最终引发从腹痛到过敏反应甚至死亡等各种症状。金标准治疗方法是从饮食中去除引发过敏的食物。然而，这种做法可能会导致营养损害和社交限制。因此，对新治疗策略的需求是显而易见的。在这种背景下，由于益生菌的免疫调节机制，人们对其进行了研究。因此，本研究的目的是在卵清蛋白（OVA）食物过敏的体内模型中研究四种益生菌菌株混合物（Probiatop®）的益生菌潜力。我们的结果表明，口服Probiatop®可减轻体重减轻，并显著降低抗OVA IgE和IgG1水平。此外，它减轻了空肠近端损伤、中性粒细胞募集和局部IL17水平。此外，益生菌混合物通过降低葡萄球菌和酵母菌的水平及频率，对肠道微生物群组成产生了积极的调节作用。总之，我们的数据表明Probiatop®有减轻IgE介导的食物过敏重要症状的潜力，表明其作为卵清蛋白食物过敏治疗辅助剂的益生菌潜力。
